Advance Search

Atherosclerotic cardiovascular disease and measurement of lipoprotein(a) levels in Italy

Cardiovascular disease and Lp(a) levels in Italy

Elena Olmastroni
Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
Manuela Casula
IRCCS MultiMedica, Sesto San Giovanni (MI), Italy and Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
Sining Xie
Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
Alberico L. Catapano
IRCCS MultiMedica, Sesto San Giovanni (MI), Italy and Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
Keywords:
Copyright and Licensing:

Copyright (c) 2024 European Atherosclerosis Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Abstract

Background: Lipoprotein(a) [Lp(a)] is a relatively new but underutilized biomarker in the context of atherosclerotic cardiovascular disease (ASCVD).
Objectives: To explore the clinical implementation of Lp(a) measurement and current practices in hospital and specialised settings in Italy.
Methods: An anonymous online questionnaire was distributed to Italian physicians to examine the habits of Italian clinicians regarding Lp(a) measurement. The survey covered three topics: 1) information on the clinical setting of the physicians, 2) questions for physicians who reported not measuring Lp(a), to understand the reasons for not requesting the test, and 3) questions for physicians who measure Lp(a), to investigate its use in patient management.
Results: A total of 978 responses were received. Overall, 63.1% of physicians reported working in a hospital; 12.2% reported being a territorial specialist. Regular Lp(a) measurement was reported by 32.1% of clinicians. Among those who do not measure Lp(a), the main barriers to implementation include high cost and limited availability of the test. The threshold value for defining elevated Lp(a) levels varies significantly among professionals, with 36.7% considering levels above 30 mg/dL to be elevated and 32.7% considering levels above 50 mg/dL to be elevated. Clinical management of patients with elevated Lp(a) primarily includes intensification of lipid-lowering therapy (69.2%), management of cardiovascular risk factors (48.7%), and lifestyle recommendations (37.4%).
Conclusions: The survey highlights the heterogeneity in the approach to managing elevated Lp(a) levels among Italian clinicians, underscoring the importance of clear guidelines and greater accessibility to the test to optimize cardiovascular risk stratification and improve clinical outcomes.

PDF
PDF

Article Metrics Graph

Article Views | PDF Downloads
Chart Graph | Range Graph

References

  1. Della Corte V, Todaro F, Cataldi M, Tuttolomondo A. Atherosclerosis and Its Related Laboratory Biomarkers. Int J Mol Sci. 2023 Oct 24;24(21):15546. https://doi.org/10.3390/ijms242115546.
  2. Duarte Lau F, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769. https://doi.org/10.1001/jamacardio.2022.0987. Erratum in: JAMA Cardiol. 2022 Jul 1;7(7):776. https://doi.org/10.1001/jamacardio.2022.2074.
  3. Jauhiainen M, Metso J, Koskinen P, Ehnholm C. Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates. Biochem J. 1991 Mar 1;274 ( Pt 2)(Pt 2):491-6. https://doi.org/10.1042/bj2740491.
  4. Kronenberg F. Lipoprotein(a). Handb Exp Pharmacol. 2022;270:201-232. https://doi.org/10.1007/164_2021_504.
  5. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. https://doi.org/10.1093/eurheartj/ehac361.
  6. Koschinsky ML, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res. 1997;27(1):14-23. https://doi.org/10.1007/BF02827238.
  7. Enkhmaa B, Anuurad E, Zhang W, Tran T, Berglund L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord. 2011 Dec;9(6):411-8. https://doi.org/10.1089/met.2011.0026.
  8. Catapano AL, Daccord M, Damato E, Humphries SE, Neely RDG, Nordestgaard BG, Pistollato M, Steinhagen-Thiessen E. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis. 2022 May;349:136-143. https://doi.org/10.1016/j.atherosclerosis.2022.02.013.
  9. Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721. https://doi.org/10.3390/ijerph20186721.
  10. Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024 Apr 3;18:100651. https://doi.org/10.1016/j.ajpc.2024.100651.
  11. Kelsey MD, Mulder H, Chiswell K, Lampron ZM, Nilles E, Kulinski JP, Joshi PH, Jones WS, Chamberlain AM, Leucker TM, Hwang W, Milks MW, Paranjape A, Obeid JS, Linton MF, Kent ST, Peterson ED, O'Brien EC, Pagidipati NJ. Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes. Am J Prev Cardiol. 2023 Mar 1;14:100478. https://doi.org/10.1016/j.ajpc.2023.100478.
  12. Catapano AL, Tokgözoğlu L, Banach M, Gazzotti M, Olmastroni E, Casula M, Ray KK; Lipid Clinics Network Group. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. Atherosclerosis. 2023 Apr;370:5-11. https://doi.org/10.1016/j.atherosclerosis.2023.02.007.
  13. Ansari S, Neely RDG, Payne J, Cegla J. Lipoprotein(a) testing in lipid clinics across the UK: Results of a national survey. J Clin Lipidol. 2024 May-Jun;18(3):e477-e481. https://doi.org/10.1016/j.jacl.2024.02.004.
  14. Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024 Apr 3;18:100651. https://doi.org/10.1016/j.ajpc.2024.100651.
  15. Khan TZ. Raised lipoprotein(a): real-world examples of communication and clinical management. Br J Cardiol. 2024 Aug;31(suppl 1):S21–S25. https://doi.org/10.5837/bjc.2024.s05
  16. Chiesa G, Zenti MG, Baragetti A, Barbagallo CM, Borghi C, Colivicchi F, Maggioni AP, Noto D, Pirro M, Rivellese AA, Sampietro T, Sbrana F, Arca M, Averna M, Catapano AL. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2023 Oct;33(10):1866-1877. https://doi.org/10.1016/j.numecd.2023.07.019.

Send mail to Author

Send Cancel

Custom technologies based on your needs

  • MongoDB
  • ElasticSearch
  • Redis
  • Solr
  • Memcached